Cell:改动化疗药物顺序 或增强抗癌效果

2012-05-16 卢秀玲 生物通

       来自麻省理工David H. Koch癌症研究所,哈佛大学的研究人员发表了一篇文章,指出换个顺序使用抗癌药物,能重排细胞凋亡信号网络,从而增强细胞死亡。相关成果公布在Cell杂志上,并被作为头条内容推荐。        领导这一研究的是麻省理工David H. Koch 癌症研究所Michael B

       来自麻省理工David H. Koch癌症研究所,哈佛大学的研究人员发表了一篇文章,指出换个顺序使用抗癌药物,能重排细胞凋亡信号网络,从而增强细胞死亡。相关成果公布在Cell杂志上,并被作为头条内容推荐。

       领导这一研究的是麻省理工David H. Koch 癌症研究所Michael B. Yaffe教授,Yaffe教授是Science Signalling科技期刊主编,主要从事癌症细胞信号研究,曾设计多种模型用于细胞信号通路研究,比如进行蛋白磷酸化预测的Scansite。

       信号通路的串扰(Crosstalk)和复杂性,以及由于致癌基因引起的信号通路波动,都会影响到通过逐个组件来分析人类疾病。而对正常信号和致癌信号,受到药物影响后出现的重排网络进行分析,将有助于科学家们更有效,特异性更强的靶向肿瘤。

       在这篇文章中,研究人员利用致癌信号通路中抑制剂,联合DNA损伤化疗分析,发现比较于同时使用几种EGFR抑制剂,错开时间来使用EGFR抑制剂,能显著提高一组三阴性乳腺癌细胞对于基因毒性药物的敏感性。所谓三阴性乳腺癌是指雌激素受体、孕酮受体和HER2检测皆为阴性的乳腺癌,这是最难治疗的癌症亚型之一,因为其生物学特征,这些癌症不会对内分泌疗法或曲妥珠单抗做出反应。

       并且研究人员还采用了系列系统分析:高密度时间依赖型信号网络检测分析,基因表达谱分析,以及包含数学模型的细胞表型应答分析,发现了一种改变细胞内状态的新方法,这一方法主要通过动态重排致癌基因信号通路来实现。这一过程能转变这些细胞的肿瘤状态,使之能更加容易受到DNA损伤诱导细胞死亡。

       而且值得注意的是,这一种DNA损伤诱导细胞死亡是通过内源性细胞凋亡重新激活来完成,在致癌基因状态下,这种内源性细胞凋亡通路的作用被抑制了。

       我们现在知道许多人类复杂疾病都是由多种因素造成的,要想研发针对此类疾病的药物,挑战颇大。目前这一领域的研究已经从靶向单个蛋白或者基因,转为了针对动态网络的,基于系统的靶向攻击。

       这项研究就是新研发方向的一个具体范例,Cell杂志同期也配发了题为“Network Medicine Strikes a Blow against Breast Cancer”的评论性文章,文章中来自哥本哈根大学的Rune Linding认为,“这项研究揭示出使用EGF受体抑制剂后,出现的信号网络进程性重排如何能够帮助治疗三阴性乳腺癌肿瘤,这证明按照时间顺序联合使用药物,能更有效的杀死癌细胞。” 

原始链接:

Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, Macbeath G, Yaffe MB. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.Cell. 2012 May 11;149(4):780-94.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958734, encodeId=68631958e3440, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jul 02 21:16:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868503, encodeId=0fbb1868503a9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 04 07:16:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506688, encodeId=4e20150668813, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581722, encodeId=9a181581e225c, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]
    2012-07-02 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958734, encodeId=68631958e3440, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jul 02 21:16:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868503, encodeId=0fbb1868503a9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 04 07:16:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506688, encodeId=4e20150668813, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581722, encodeId=9a181581e225c, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958734, encodeId=68631958e3440, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jul 02 21:16:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868503, encodeId=0fbb1868503a9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 04 07:16:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506688, encodeId=4e20150668813, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581722, encodeId=9a181581e225c, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958734, encodeId=68631958e3440, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jul 02 21:16:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868503, encodeId=0fbb1868503a9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 04 07:16:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506688, encodeId=4e20150668813, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581722, encodeId=9a181581e225c, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]